CS-121 vs Plozasiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Familial Chylomicronemia Syndrome

Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline

CS-121

Developed by CorrectSequence Therapeutics

Phase 1 in Familial Chylomicronemia Syndromegene editing (base editing)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07176923 (registry estimate)

No aligned efficacy figure on record for this race.

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Approved in Familial Chylomicronemia SyndromeRNAi (siRNA)
Partial signal

NCT05089084 · Phase 3 · completed

The study randomly assigned 75 participants to plozasiran or placebo and used quadruple masking, with 25 mg, 50 mg, and pooled placebo groups. The primary fasting-triglyceride endpoint was statistically significantly improved for both doses, but it was a laboratory surrogate rather than a hard clinical or endoscopic outcome, supporting a moderate grade.

Reported efficacy

Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) (met)

Result source: NCT05089084

Results for Familial Chylomicronemia Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

CS-121: no structured comparison results are available for Familial Chylomicronemia Syndrome.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Plozasiran

Triglycerides -80.1% (n=24) vs -17.1% (n=19) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 5 more results
-77.7% (n=24) vs -2.6% (n=19) placebo25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-61.5% (n=26) vs 0.72% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-77.6% (n=22) vs -17.1% (n=19) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-71% (n=22) vs -2.6% (n=19) placebo50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-45.38% (n=24) vs 0.72% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Non-HDL-C -38.69% (n=26) vs 3.67% (n=25) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 3 more results
-38.16% (n=26) vs 6.72% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-36.12% (n=24) vs 3.67% (n=25) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-25.48% (n=24) vs 6.72% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
HDL-C 65.48% (n=26) vs 2.89% (n=25) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 3 more results
61.9% (n=26) vs 20.61% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
72.02% (n=24) vs 2.89% (n=25) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
74.52% (n=24) vs 20.61% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Available safety results

Plozasiran

Dropout rate
11.5%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
8.3%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Discontinued due to AEs
7.7%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
4.2%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Serious AEs
19.2%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
8.3%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Most frequent reported AEs
25 mg
abdominal pain 26.9% (placebo 28%)
covid-19 19.2% (placebo 4%)
nasopharyngitis 19.2% (placebo 16%)
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
50 mg
abdominal pain 29.2% (placebo 28%)
covid-19 29.2% (placebo 4%)
headache 20.8% (placebo 8%)
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3

Severe Hypertriglyceridemia

Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline

CS-121

Developed by CorrectSequence Therapeutics

Phase 1 in Severe Hypertriglyceridemiagene editing (base editing)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2028 · NCT07657780 (registry estimate)

No aligned efficacy figure on record for this race.

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Phase 3 in Severe HypertriglyceridemiaRNAi (siRNA)
Partial signal

NCT06347003 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: March 2029 · NCT06880770 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Severe Hypertriglyceridemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

CS-121: no structured comparison results are available for Severe Hypertriglyceridemia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Plozasiran

Fasting TG -74.2% (n=55) vs -17.2% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 29 more results
-77.6% (n=57) vs 7.2% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.8% (n=57) vs -0.7% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=57) vs -7.3% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-76.3% (n=57) vs -2.9% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-75.6% (n=57) vs 2.4% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.2% (n=57) vs -17.2% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.8% (n=57) vs -11.7% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.6% (n=57) vs -7.6% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=54) vs -17.2% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.5% (n=55) vs 7.2% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=55) vs -0.7% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.9% (n=55) vs -7.3% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-80.1% (n=55) vs -2.9% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-75.3% (n=55) vs 2.4% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=55) vs -17.2% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=55) vs -11.7% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64% (n=55) vs -7.6% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-66% (n=50) vs -17.2% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-63.3% (n=54) vs 7.2% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-54% (n=54) vs -0.7% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.9% (n=54) vs -7.3% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.5% (n=54) vs -2.9% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-67.7% (n=54) vs 2.4% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-66% (n=54) vs -17.2% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-60% (n=54) vs -11.7% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-37.7% (n=54) vs -7.6% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Apo C3 -79.4% (n=55) vs 114.2% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 56 more results
-84.6% (n=57) vs 209.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.9% (n=57) vs 146.3% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs 122.2% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-87.1% (n=57) vs 134.4% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84% (n=57) vs 118.8% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.4% (n=57) vs 114.2% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.7% (n=57) vs 140.2% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.9% (n=57) vs 152% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-83.2% (n=57) vs 7% (n=57) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.7% (n=57) vs 4.7% (n=57) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.2% (n=57) vs 0% (n=57) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.3% (n=57) vs 2.8% (n=57) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.6% (n=57) vs 7.8% (n=57) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.2% (n=57) vs -0.8% (n=57) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs -2.2% (n=57) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58.3% (n=57) vs 0.2% (n=57) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.7% (n=54) vs 114.2% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.4% (n=55) vs 209.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.8% (n=55) vs 146.3% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.8% (n=55) vs 122.2% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.4% (n=55) vs 134.4% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-81.2% (n=55) vs 118.8% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.7% (n=55) vs 114.2% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.9% (n=55) vs 140.2% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-60.9% (n=55) vs 152% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.9% (n=55) vs 7% (n=57) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.2% (n=55) vs 4.7% (n=57) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=55) vs 0% (n=57) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.9% (n=55) vs 2.8% (n=57) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.7% (n=55) vs 7.8% (n=57) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.1% (n=55) vs -0.8% (n=57) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=55) vs -2.2% (n=57) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.1% (n=55) vs 0.2% (n=57) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.6% (n=49) vs 114.2% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-67.3% (n=54) vs 209.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.8% (n=54) vs 146.3% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-55.5% (n=54) vs 122.2% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.1% (n=54) vs 134.4% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.7% (n=54) vs 118.8% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.6% (n=54) vs 114.2% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.4% (n=54) vs 140.2% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-50.2% (n=54) vs 152% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-65.1% (n=53) vs 7% (n=57) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-57.3% (n=53) vs 4.7% (n=57) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.2% (n=53) vs 0% (n=57) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.8% (n=53) vs 2.8% (n=57) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.9% (n=53) vs 7.8% (n=57) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-68.1% (n=53) vs -0.8% (n=57) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-63% (n=53) vs -2.2% (n=57) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.5% (n=53) vs 0.2% (n=57) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Non-HDL-C -21.7% (n=55) vs -1.5% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 29 more results
-26.1% (n=57) vs 6.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-20.7% (n=57) vs 4.5% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-22.3% (n=57) vs 1.4% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23.7% (n=57) vs 1.8% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-22.9% (n=57) vs 5.7% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-21.7% (n=57) vs -1.5% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-24% (n=57) vs -2.3% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.1% (n=57) vs -0.3% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-28.4% (n=54) vs -1.5% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.7% (n=55) vs 6.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-30.7% (n=55) vs 4.5% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-30% (n=55) vs 1.4% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-37.8% (n=55) vs 1.8% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.6% (n=55) vs 5.7% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-28.4% (n=55) vs -1.5% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.3% (n=55) vs -2.3% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23.8% (n=55) vs -0.3% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-29.4% (n=49) vs -1.5% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27% (n=54) vs 6.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.7% (n=54) vs 4.5% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.3% (n=54) vs 1.4% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27.9% (n=54) vs 1.8% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-26.7% (n=54) vs 5.7% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-29.4% (n=54) vs -1.5% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-27.4% (n=54) vs -2.3% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-19.2% (n=54) vs -0.3% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
HDL-C 67.6% (n=55) vs 10.6% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 29 more results
88.1% (n=57) vs 4.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.7% (n=57) vs 6.2% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
62.5% (n=57) vs 11.3% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
82.6% (n=57) vs 5.7% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
81.2% (n=57) vs 8.8% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.6% (n=57) vs 10.6% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
68% (n=57) vs 10.2% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
47.2% (n=57) vs 11.7% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
62.8% (n=54) vs 10.6% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
76.2% (n=55) vs 4.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
73.5% (n=55) vs 6.2% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
60.2% (n=55) vs 11.3% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
87.1% (n=55) vs 5.7% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
78.7% (n=55) vs 8.8% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
62.8% (n=55) vs 10.6% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
67.2% (n=55) vs 10.2% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
51.1% (n=55) vs 11.7% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
54.2% (n=49) vs 10.6% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
53.4% (n=54) vs 4.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
45.4% (n=54) vs 6.2% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
39.9% (n=54) vs 11.3% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
66.2% (n=54) vs 5.7% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
61.2% (n=54) vs 8.8% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
54.2% (n=54) vs 10.6% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
48.2% (n=54) vs 10.2% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
34.5% (n=54) vs 11.7% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Apo B 0.7% (n=55) vs 8% (n=59) placebo @ 24wk50 mg
percent change · % of baseline
NCT04720534 · Phase 2 · registry result, not featured evidence
show 29 more results
-1.9% (n=57) vs 16.2% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.5% (n=57) vs 16% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-1.3% (n=57) vs 4.2% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.6% (n=57) vs 5.3% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
4.4% (n=57) vs 1.6% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.7% (n=57) vs 8% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.6% (n=57) vs 3.9% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
8.5% (n=57) vs 8.9% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-5.3% (n=54) vs 8% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-9% (n=55) vs 16.2% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-7.2% (n=55) vs 16% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-11.2% (n=55) vs 4.2% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-13.1% (n=55) vs 5.3% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10.3% (n=55) vs 1.6% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-5.3% (n=55) vs 8% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-6% (n=55) vs 3.9% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
2.5% (n=55) vs 8.9% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6% (n=49) vs 8% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-2.3% (n=54) vs 16.2% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.8% (n=54) vs 16% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0.5% (n=54) vs 4.2% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.8% (n=54) vs 5.3% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.7% (n=54) vs 1.6% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6% (n=54) vs 8% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-1.3% (n=54) vs 3.9% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-0.4% (n=54) vs 8.9% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Available safety results

Plozasiran

Dropout rate
7%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
5.5%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
9.1%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.8%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
0%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.8%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Serious AEs
12.5%50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
3.6%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.4%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mg
covid-19 16.1% (placebo 14.8%)
upper respiratory tract infection 12.5% (placebo 6.6%)
type 2 diabetes mellitus 10.7% (placebo 4.9%)
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
25 mg
covid-19 16.4% (placebo 14.8%)
headache 10.9% (placebo 4.9%)
sinusitis 7.3% (placebo 0%)
NCT04720534 · Phase 2 · registry result, not featured evidence
10 mg
covid-19 20.4% (placebo 14.8%)
headache 14.8% (placebo 4.9%)
urinary tract infection 11.1% (placebo 9.8%)
NCT04720534 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CS-121's landscape · Plozasiran's landscape